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Cyclooxygenase (COX) enzymes are molecular targets of nonsteroidal anti-inflammatory drugs (NSAIDs), the most used
medication worldwide. However, the COX enzymes are not the sole molecular targets of NSAIDs. Recently, we showed that two
NSAIDs, diclofenac and meclofenamate, also act as openers of Kv7.2/3 K
+ channels underlying the neuronal M-current. Here we
designed new derivatives of diphenylamine carboxylate to dissociate the M-channel opener property from COX inhibition. The
carboxylate moiety was derivatized into amides or esters and linked to various alkyl and ether chains. Powerful M-channel
openers were generated, provided that the diphenylamine moiety and a terminal hydroxyl group are preserved. In transfected
CHO cells, they activated recombinant Kv7.2/3 K
+ channels, causing a hyperpolarizing shift of current activation as measured
by whole-cell patch-clamp recording. In sensory dorsal root ganglion and hippocampal neurons, the openers hyperpolarized
the membrane potential and robustly depressed evoked spike discharges. They also decreased hippocampal glutamate and
GABA release by reducing the frequency of spontaneous excitatory and inhibitory post-synaptic currents. In vivo, the openers
exhibited anti-convulsant activity, as measured in mice by the maximal electroshock seizure model. Conversion of the
carboxylate function into amide abolished COX inhibition but preserved M-channel modulation. Remarkably, the very same
template let us generating potent M-channel blockers. Our results reveal a new and crucial determinant of NSAID-mediated
COX inhibition. They also provide a structural framework for designing novel M-channel modulators, including openers and
blockers.
Citation: Peretz A, Degani-Katzav N, Talmon M, Danieli E, Gopin A, et al (2007) A Tale of Switched Functions: From Cyclooxygenase Inhibition to M-
Channel Modulation in New Diphenylamine Derivatives. PLoS ONE 2(12): e1332. doi:10.1371/journal.pone.0001332
INTRODUCTION
Cyclooxygenase (COX) enzymes catalyze the conversion of
arachidonic acid into prostaglandin H2 (PGH2), the early step
in the biosynthesis of prostanoids [1]. The COX enzymes are
functional homodimers, where each subunit contains both a
cyclooxygenase and a peroxidase active site. Three COX isozymes
have been characterized so far, COX-1, COX-2, and COX-3.
While COX-1 is a ubiquitous constitutive form of the enzyme that
is involved in the regulation of various physiological processes such
as platelet aggregation or homeostasis of the gastrointestinal tract
and kidneys, the COX-2 isozyme expression is mainly observed
during inflammatory processes [1,2]. COX-2 is constitutively
expressed in some tissues, but can be induced by different stimuli
such as growth factors or interleukin-1. All NSAIDs inhibit the
COX isozymes to different extents, which accounts for their anti-
inflammatory and analgesic properties as well as their gastroin-
testinal side effects, the latter being more related to COX-1
inhibition [3]. Hence, the development of COX-2-selective
inhibitors as nonulcerogenic, anti-inflammatory, and analgesic
agents was greatly stimulated. However, the recent withdrawal of
diarylheterocyclic selective COX-2 inhibitors due to adverse
cardiovascular side effects toned down the initial enthusiasm
surrounding the launch of selective anti-COX-2 drugs [4–6].
The COX enzymes are not the sole the molecular targets of
NSAIDs. Recently, we showed that two chemically-related
NSAIDs, diclofenac and meclofenamic acid also act as openers
of Kv7.2/3 (KCNQ2/3) potassium channels [7], shown to
underlie the neuronal M-currents. The M-channels generate a
subthreshold, noninactivating voltage-gated K
+ current that plays
an important role in controlling neuronal excitability [8]. M-
channels are thought to mediate early spike frequency adaptation
by producing a medium after-hyperpolarization (mAHP) [8–11].
M-currents also activate during the spike afterdepolarization
(ADP) limiting its amplitude and duration, thus preventing its
escalation to a burst [12]. Reflecting their physiological importance,
mutations of the Kv7.2 and Kv7.3 genes have been identified as
causes of myokymia and of benign familial neonatal convulsions, a
neonatal form of epilepsy [10]. Pharmacological targeting of M-
channels is of great clinical importance. While openers demonstrate
a therapeutic potential for the treatment of neuronal hyperexcit-
ability like migraine, epilepsy and neuropathic pain, blockers are
potentially useful for the treatment of memory deficits and
Alzheimer’s disease [13,14]. Here, we generated a series of novel
derivatives of diphenylamine carboxylate to discriminate the M-
channel modulatory activity from the COX inhibition. For this
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PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1332purpose, we derivatized the carboxylate functionality into amides or
esters which were attached to different alkyl and ether chains. We
obtained potent M-channel openers with or without COX
inhibition. Conversion of the carboxylate moiety into amide
successfully removes the COX inhibition but preserves the M-
channel modulation. Our data disclose an important and novel
determinant of COX inhibition by the diclofenac and N-
phenylanthranilic acid NSAID subfamilies. A structural framework
is now available for the design of novel and selective M-channel
modulators and for tailoring independently potent new NSAIDs.
RESULTS
Carboxylate derivatization of diclofenac and
meclofenamic acid
Knowing the non-selective inhibition of COX-1 and COX-2
enzymes displayed by diclofenac and meclofenamic acid [15] as
well as their recently described M-channel opener properties [7],
our purpose was to design potentially powerful M-channel
openers, devoid of substantial anti-COX activity. The carboxylate
group of diclofenac and meclofenamic acid was derivatized into
amides or esters and linked to different alkyl or ether chains of
various lengths (Table 1 and Table S1). In addition, the aromatic
rings of the diphenylamine moiety were substituted with different
electron donating or withdrawing groups. In a first screen, two
parameters were checked: (a) the non-selective inhibition of COX-
1/COX-2 enzyme activities, measured by the production of PGE2
in cultured mouse colon adenocarcinoma (CT26) and mouse
Lewis lung carcinoma cells (D122) cells; (b) the M-channel activity,
measured by the heterologous coexpression of Kv7.2 and Kv7.3
subunits in Chinese hamster ovary (CHO) cells.
Considering the COX activity, it is striking to note that all the
amide derivatives of diclofenac (compounds 1, 2, 4, 6 and 7) and
meclofenamic acid (compounds 16–18) produced very weak or no
inhibition of the COX enzymes in CT26 and D122 cells (IC50
.50 mM; Table 1 and Table S1). This virtual lack of inhibition of
the COX activity was displayed by amides derivatives bearing ether
as well as alkyl chains (e.g., compounds 2 and 7). While the issue of
the COX selectivity was not directly addressed in this study, we
tentatively assume that the lack of COX inhibition displayed by the
various amide compounds involves both COX-1 and COX-2, since
the D122 cell line is endowed with both COX-1 and COX-2
activities and the CT26 line expresses mainly though not exclusively
COX-2 [16,17]. These features contrast with the well known anti-
COX-1/COX-2 properties of the parental templates [15]. In
contrast, all ester compounds tested, produced a potent inhibition of
the COX enzymes (IC50s,1 to 230 nM) (Table 1 and Table S1).
The prominent difference in COX inhibition between amide and
ester derivatives is well illustrated with compounds 2 and 8 or with
compounds 7 and 15 (Table 1, Table S1 and Figure 1). Comparison
of compounds 8 and 13 suggests that the terminal hydroxyl
functionality of the ester derivatives is not important for the anti-
COX activity. Compound 13 is even more powerful than the parent
diclofenac template. Similarly, a potent and non-selective inhibition
of purified COX-1 and COX-2 enzymes was obtained with
compounds 8 and 13 and diclofenac. Thus, at 1 mM concentration
compounds 8, 13 and diclofenac respectively produced 5861%,
5961% and 6462% inhibition of the purified ovine COX-1
enzyme (n=3) and 8561%, 8361% and 7262% inhibition of the
human recombinant COX-2 enzyme (n=3).
Considering the M-channel activity, several important features
could be deduced from the structure-activity relation (SAR) study
(Table 1, Table S1 and Figure 2). In contrast to the dramatic impact
ofthe carboxylateconversion intoamide onCOX inhibition, theM-
channel openers can clearly accommodate with carboxylate, ester
and amide functionalities. Table 1 and Table S1 show that openers
of the Kv7.2/3 channels are found in compounds bearing a
carboxylate (e.g., compound 3, diclofenac, or meclofenamate), an
ester group (e.g., compounds 8, 9 and 15) as well as an amide
function (e.g., compounds 2, 6, 7 and 16). The opener activity is also
displayed by derivatives bearing either ether or alkyl chains (e.g.,
compounds 4–7 and 2 or 8 and 9). As the main opener effect of the
various compounds is to cause a hyperpolarizing shift of the activa-
tion curve of Kv7.2/3 channels, the extent of the left-shift (DV50)i sa
faithful measure of the opener potency (Table 1 and Table S1).
Hence, we found that substituting the aromatic rings with NO2
groups significantly increased the left-shift in activation. In the ester
series, compound 9 is a much weaker opener (DV50=24.1 mV)
than compound 15 which bears one NO2 (DV50=231.0 mV).
Similarly, in the amide series, compound 6 possessing three NO2 is a
stronger opener (DV50=231.3 mV) than compound 7 which bears
only one NO2 (DV50=212.2 mV).
The diphenylamine moiety itself appears to be important for
activating the M-channels. We found that NSAID compounds
lacking this group but still holding a carboxylate function like
ibuprofen, flurbiprofen, ketoprofen, fenoprofen or naproxen, do
Table 1. SAR studies of derivatives of diclofenac and
meclofenamic acid.
......................................................................
Compound
COX inhibition
(IC50, mM)
M-channels (Kv7.2/
Kv7.3)
DV50
(mV)
CT26 D122
Diclofenac 0.003 0.1 opener (EC50=2.6 mM) 214.5
Meclofenamic acid nd nd opener (EC50=25mM) 222.7
1 .50 .50 opener nd
2 40 30 opener (EC50=7mM) 212.6
3 nd nd opener nd
4 10 15 opener nd
5 nd nd opener nd
6 .50 .50 opener (EC50=14mM) 231.3
7 .50 .50 opener (EC50=17mM) 212.2
8 0.015 0.003 opener (EC50=18mM) 218.7
9 0.010 0.001 opener 24.1
10 nd nd inactive
11 nd nd blocker
12 nd nd inactive
13 0.001 0.010 blocker
14 nd nd blocker
15 0.048 0.229 opener (EC50=22mM) 231.0
16 20 5 opener (EC50=3mM) 28.4
17 20 50 opener (EC50=9mM) 25.5
18 0.5 30 opener (EC50=6mM) 23.7
19 nd nd inactive
20 nd nd inactive
COX inhibition was measured by the production of PGE2 in cultured mouse
colon adenocarcinoma (CT26) and mouse Lewis lung carcinoma cells (D122)
cells. IC50 values in mM represent the average values from two experiments,
each performed in triplicate. The impact of the compounds on M-channel
activity was measured by the heterologous coexpression of Kv7.2 and Kv7.3
subunits in CHO cells. EC50 values in mM represent the average values of opener
potency as determined by the concentration-dependent left-shift in the half-
activation potential DV50 (mV) and fitted by a sigmoidal function (n=3–5).
doi:10.1371/journal.pone.0001332.t001
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PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1332not activate Kv7.2/3 channels, while those bearing both
functionalities (diphenylamine and carboxylate) such as N-
phenylanthranilic acid drugs (mefenamate, tolfenamate, or
flufenamate) are all M-channel openers (Figure 3). Noteworthy,
our data indicate that a terminal hydroxyl group in the ether or
alkyl chain is absolutely required to obtain an active M-channel
opener. For example, the compounds 10, 12, 19 and 20 whose
terminal hydroxyl function has been replaced by methyl or
isobutyl groups are totally inactive vis-a `-vis Kv7.2/3 channels
(Table 1, Table S1 and Figure 2). Remarkably, in the diclofenac
series we obtained potent M-channel blockers with compounds 11,
13 and 14 where the terminal hydroxyl has been replaced by
isobutyl, ethylamine and 2,3-epoxypropyl groups, respectively
(Table 1 and Table S1). When tested on recombinant Kv7.2/3
channels that were heterologously expressed in CHO cells,
compound 13 potently and dose-dependently produced a blockade
of the K
+ currents (IC50=11mM). At 25 mM compound 13
produced more than 90 % inhibition of the Kv7.2/3 current at a
wide range of membrane potentials (from 260 to +50 mV;
Figure 4A and B). Recent work suggested that M-currents play a
key role in controlling the excitability of sensory dorsal root
ganglion (DRG) neurons and may therefore represent a thera-
peutic target for the treatment of pain [18]. Hence, measuring the
effects of novel M-channel modulators on DRG neuronal
excitability is of important value, considering their potential
impact on nociceptive signaling pathways. We examined in the
current-clamp configuration the effects of compound 13 on spike
activity of cultured rat DRG neurons (Figure 4C). A single spike
discharge pattern was evoked by injecting a minimal depolarizing
current pulse (,10 pA, 400 ms). Within 2 min, external applica-
tion of 1 mM compound 13 depolarized the DRG membrane
potential (DV=+761 mV) and potently increased the number of
evoked spikes (,10–20 pA for 400 ms, from 160t o1 2 62; n=5,
p,0.01) (Figure 4C). The hyperexcitability profile of compound
13 (1 mM) on spike generation was reflected by a decrease in
rheobase current of about 300 pA that is needed to generate a
single spike (for a 2 ms injection, from 650671 pA to 347644 pA,
n=6; p,0.01). The hyperexcitability discharge pattern induced
by this M-channel blocker was so strong that in some cases, it
could lead the DRG neurons to fire spontaneously, with no need
of injecting depolarizing current (Figure 4D).
M-channel opener properties of compound 15, an
ester derivative that also inhibits COX enzymes
As described above, we found that the ester compound 15 of the
diclofenac series was both an inhibitor of the COX enzymes but
also a potent opener of M-channels. We analyzed in more details
Figure 1. Inhibition of COX activity by compounds 7 and 15. The inhibition of COX enzyme activity was measured by the production of PGE2 in
cultured mouse colon adenocarcinoma cells (CT26). While the COX activity is inhibited by the ester compound 15 (IC50=69 nM), it is completely
unaffected by the amide compound 7. This typical experiment gave similar results in two additional trials. Shown are the chemical structures of
compounds 7 and 15.
doi:10.1371/journal.pone.0001332.g001
Figure 2. Pharmacophoric features of M-channels deduced from SAR
studies of diphenylamine derivatives.
doi:10.1371/journal.pone.0001332.g002
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PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1332its opener properties in vitro and in vivo. Figure 5A (left panel) shows
representative traces of Kv7.2/3 channels expressed in CHO cells.
External application of compound 15 enhanced Kv7.2/3 currents
at nearly all voltages (right panel). However, like all openers
described in this study, the effects of compound 15 were voltage-
dependent. As the test potentials were more positive (above -
10 mV), the effects of compound 15 became weaker on current
amplitude. When membrane potential was stepped every 30 sec
from 290 to 250 mV, application of 10 mM and 50 mMo f
compound 15 produced 3.2- and 9.1-fold increase in current
amplitude, respectively (n=10; Figure 5B–D). The drug action
had a fast onset as within one minute of compound 15 superfusion,
the current increased significantly. When we analyzed the
conductance/voltage relationships, it was clear that the activating
effect of compound 15 mainly arises from a left-shift in the Kv7.2/
3 activation curve. For example, 10 mM, 50 mM and 200 mMo f
compound 15respectivelyproducedleft-shiftsof211 mV,221 mV
and 231 mV compared to control, with no change in the
Boltzmann slopes (Figure 5E and F; V50=232.168.9 mV,
n=19; V 50=243.669.0 mV, n=5; V50=253.569.3 mV, n=5
and V50=263.162.0 mV, n=5, respectively). The opener action
of compound 15 was concentration-dependent and was quantified
by the extent of the left-shift (DV50), yielding an EC50 of 22 mM.
Compound 15 also affected Kv7.2/3 gating by accelerating the
activation kinetics (from t1/2=296663 ms to t1/2=171629 ms,
n=6; p,0.05; Figure 6A and B). Comparison of the tail currents at
260 mV revealed that compound 15 markedly slowed down the
deactivation kinetics of Kv7.2/3 channels (from tdeact=129622 ms
to tdeact=284643 ms; n=5, p,0.01; Figure 6C and D).
We further characterized the properties of compound 15 on
central and peripheral neurons, using the current-clamp mode of
the whole-cell patch-clamp technique in rat primary cultures of
hippocampal and DRG neurons (Figure 7). Repetitive spike
discharges were evoked by depolarizing current injections.
External application of compound 15 (25 mM) robustly and
reversibly depressed the number of evoked action potentials in
both hippocampal and DRG neurons (from 9.661.0 to 2.160.5,
n=8 and from 10.460.8 to 0.860.3, n=8 respectively; 75–200
pA for 400 ms; p,0.01) (Figure 7A and D). Exposure to com-
pound 15 (25 mM) hyperpolarized the resting membrane potential
of DRG neurons by 28.360.2 mV (from 260.660.3 mV to
269.060.3 mV, n=13; p,0.01; Figure 7B). A similar hyperpo-
larization was also obtained in hippocampal neurons exposed to
compound 15 (28.5 mV). Reflecting the dampening action of
compound 15 on spike generation, the rheobase current needed to
be injected into DRG neurons to generate a single spike, was
increased upon exposure to the drug (for a 2 ms injection, from
400641 pA to 577638 pA, n=12; p,0.01) (Figure 7C and E).
Because of their slow activation and their lack of inactivation,
M-channels could modulate neuronal activity during repetitive
spike discharge and tune neurotransmitter release. Figure 8
illustrates the effect of compound 15 on synaptic transmission
and transmitter release. Spontaneous excitatory and inhibitory
post-synaptic currents (sEPSCs and sIPSCs) were recorded from
dense cultures of primary hippocampal neurons, using the voltage-
clamp configuration of the whole-cell patch-clamp technique. The
sIPSCs were recorded at a holding potential of 270 mV and were
pharmacologically isolated by blocking NMDA and AMPA
receptor-mediated excitatory postsynaptic currents (with 10 mM
AP-5 and 10 mM NBQX); sIPSCs were exclusively mediated by
the activation of GABAA Cl
2 channels as they could be com-
pletely blocked with 30 mM picrotoxin and 10 mM bicuculline (not
shown). Hence, sIPSCs reflect the synaptic release of GABA.
Compound 15 (25 mM) powerfully and reversibly inhibited
sIPSCs, mainly by depressing their frequency of spontaneous
occurrence (more than 98% inhibition, Figure 8A–C). Compound
15 did not significantly affect the amplitude and the kinetics of the
currents. Spontaneous EPSCs were recorded at 270 mV and
Figure 3. Chemical structures of NSAIDs lacking the diphenylamine moiety but still bearing a carboxylate function like ibuprofen, flurbiprofen,
ketoprofen, fenoprofen and naproxen. Chemical structures of N-phenylanthranilic acid drugs containing the diphenylamine moiety like
mefenamate, tolfenamate and flufenamate.
doi:10.1371/journal.pone.0001332.g003
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mediated inhibitory post-synaptic currents (with 10 mM bicucul-
line and 30 mM picrotoxin). The sEPSCs were solely mediated by
the activation of AMPA receptors and to a lesser extent of NMDA
receptors, as they were blocked by 10 mM NBQX and 10 mM AP-
5. Thus, sEPSCs reflect the synaptic release of glutamate. Under
control conditions, sEPSCs appeared as repetitive bursts whose
frequency was variable, ranging from 0.3 to 2 Hz and increasing
with the density of the hippocampal culture. Application of
compound 15 markedly reduced the burst duration of sEPSCs
without a significant effect on the amplitude (Figure 8D–F).
Consequently, compound 15 reduced by about 50% the total
charge transfer as well as the charge transfer within the bursts
(Figure 8D–F). Interestingly, activation of M-channels by com-
pound 15 did not affect the amplitude and the kinetics of
miniature EPSCs and IPSCs (not shown).
Given its dampening action on neuronal spiking discharges, we
checked for a possible anti-convulsant effect of compound 15 in
the maximal electroshock seizure (MES) model in mice. This test is
generally thought to be a model of generalized tonic-clonic seizure
in human [19]. MES produced hind limb extension in all mice
that received intraperitoneal injection of vehicle solution. Intra-
peritoneal injection of compound 15 30 min before the electro-
shock, dose-dependently (1–40 mg/kg) protected the animals
against the tonic extension caused by MES, with an ED50 of
12 mg/kg (Figure 8G). For comparison, intraperitoneal injection
of phenytoin and sodium valproate 30 min before the electroshock
fully prevented hind limb extension at doses of 20 mg/kg and
500 mg/kg, respectively (not shown).
M-channel opener properties of compound 6, an
amide derivative that does not inhibit COX enzymes
As mentioned above, we succeeded to design an amide derivative of
the diclofenac series, which displays a potent M-channel activity but
does not inhibit COX-1/COX-2 enzymes. We characterized further
its action on recombinant Kv7.2/3 channels expressed in CHO cells
and its properties on primary cultured neurons. Superfusion of
compound 6 enhanced Kv7.2/3 currents at all voltages. Like
compound 15, the activating effects of compound 6 became weaker
when membrane voltage was stepped to more positive potentials
(Figure 9A). At 250 mV, a physiologically relevant subthreshold
potential, compound 6 (25 mM) increased Kv7.2/3 current ampli-
tude by 9.461.2 fold (n=5). The activating effect of compound 6
mostly originated from a left-shift of the Kv7.2/3 activation curve.
For example, 10 mM and 100 mM of compound 6 produced left-
shifts of 213 mV and 231 mV, respectively, compared to control
(Figure 9B and C). Compound 6 dose-dependently activated Kv7.2/
3 channels, a feature quantified by the concentration dependent left-
shift (DV50), yielding an EC50 of 14 mM( F i g u r e9 C ) .
We examined the selectivity of compound 6 on other relevant
Kv channels expressed in Xenopus oocytes (Table 2). Except for a
moderate inhibition of Kv1.2 and Kv7.1 currents (34% and 23 %,
Figure 4. Compound 13 inhibits Kv7.2/3 currents and enhances firing of peripheral DRG neurons. (A) Representative traces recorded from the
same CHO cell before (left panel) and after (right panel) external application of compound 13 (25 mM). The membrane potential was stepped from
290 mV (holding potential) to +50 mV for 1.5 s pulse duration in 10 mV increments, followed by a repolarizing step to 260 mV. (B) Current density-
voltage relations in the absence (empty squares) and presence of compound 13 (25 mM) (solid squares) (n=6). (C) Representative rat DRG spiking
discharge, evoked by a squared depolarizing current pulse (10 pA for 400 msec) before (control), during exposure to 1 mM compound 13 for 1, 2 and
3 min. (D) Representative trace of spontaneously spiking DRG neuron previously exposed (5 min) to 1 mM compound 13.
doi:10.1371/journal.pone.0001332.g004
A Tale of Switched Functions
PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1332respectively), compound 6 (50 mM) did not affect the current
amplitude of Kv11.1 (hERG), Kv2.1 and Kv4.3. Among the Kv7
channel family, compound 6 appeared to act as an opener of
Kv7.2 but not of Kv7.1 and Kv7.4. We found that compound 6
could also activate Kv7.3 when tested on the Kv7.3 mutant
A315T [20]. Noteworthy, compound 6 (25 mM) did not affect the
amplitude of miniature excitatory and inhibitory post-synaptic
currents (mEPSCs and mIPSCs) in cultured hippocampal neurons,
suggesting that it does not interact with AMPA/NMDA and
GABAA channels (not shown).
Superfusion of compound 6 (25 mM) powerfully and reversibly
reduced the number of evoked action potentials in DRG neurons
(from 8.760.8 to 0.960.1, n=12; 75–250 pA for 400 ms;
p,0.001) (Figure 9D and F). Exposure to compound 6 hyperpo-
larized the resting membrane potential of DRG neurons by
29.061.9 mV (from 256.062.2 mV to 265.063.4 mV, n=7;
p,0.01; Figure 9G). The rheobase current needed to generate a
single spike in DRG neurons was increased upon exposure to
compound 6 (for a 2 ms injection, from 178636 pA to 300655 pA,
n=8; p,0.005) (Figure 9E).
Figure 5. M-channel opener properties of compound 15 on Kv7.2/3 channels expressed in CHO cells. (A) Representative traces recorded from the
same cell before (left panel) and after (right panel) external application 50 mM compound 15. The membrane potential was stepped from 290 mV
(holding potential) to +10 mV for 1.5 s pulse duration in 10 mV increments, followed by a repolarizing step to 260 mV. (B) and (C) Cells were
stepped from 290 mV to 250 mV every 30 sec for 1.5 sec pulse duration. Current traces were recorded from the same cell in the absence (control)
and presence of 10 mM (B) and 50 mM( c) compound 15. (D) The percentage of the current recorded at 250 mV is shown in the presence of 10 mM
and 50 mM compound 15 or in its absence, the latter being the control of 100% (n=10; * p,0.01). (E) The normalized conductance (G/Gmax) was
plotted as a function of the test voltages, for control (open squares), 10 mM (solid squares) and 50 mM (diamonds) compound 15-treated cells. The
activation curves were fitted using one Boltzmann function (n=5). (F) The potency of compound 15 was determined by the extent of left-shift (DV50),
plotted as a function of compound 15 concentration and fitted by a sigmoidal function yielding an EC50 value of 2261 mM (n=5).
doi:10.1371/journal.pone.0001332.g005
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Based on carboxylate derivatization into amides and esters, our
data reveals a crucial determinant of COX inhibition by the
diclofenac and meclofenamate NSAID subfamilies. The SAR
study indicates that the conversion of the carboxylate group to
amide functionality efficiently dissociates the COX inhibition from
the M-channel modulation, generating M-channel openers free of
significant anti-COX activity. This functional switch is clearly
observed with the amide derivatives of the diclofenac series,
compounds 1, 2, 4, 6 and 7, which lack substantial COX enzyme
inhibition but are all M-channel openers, provided that a terminal
hydroxyl function is maintained (Figure 2, see below). This feature
contrasts with the ester derivatives of the same diclofenac series,
compounds 8, 9 and 15, which are powerful COX inhibitors as
well as M-channel openers. The same characteristics are observed
with the amide derivatives of the meclofenamate series such as
compounds 16–18. In previous SAR studies, attempts were made
for derivatizing the carboxylate moiety of various NSAIDs to
esters and amides in order to produce selective COX-2 inhibitors
or antimycobacterial agents [21–25]. For example, diclofenac
amide derivatives were recently found to exhibit enhanced
antimycobacterial activity [25]. Esters, primary and secondary
amides of indomethacin were shown to be selective COX-2
inhibitors [22,23]. Unlike the indomethacin series, wherein both
esters and amides are potent and selective COX-2 inhibitors, SAR
studies on meclofenamic acid analogues suggest that only some
amide derivatives are capable of COX-2-selective inhibition
[22,24]. However, it was found that introduction of a terminal
hydroxyl group in the alkyl chain leads to significant loss in
potency and selectivity [22,24]. Interestingly, all amide com-
pounds characterized in this work possess a terminal hydroxyl
moiety. Hence, the combination of the amide function and the
preservation of a terminal hydroxyl group are probably respon-
sible for the profound loss of COX inhibition displayed by the
amide derivatives, designed in this study.
The active site of COX-1 and COX-2 isozymes is a narrow
hydrophobic channel extending from the membrane binding
domain to the core of the catalytic domain [1,26]. In the apex of
the channel, both enzymes possess a conserved Ser530 correspond-
ing to the residue acetylated by aspirin and a conserved Tyr385,
which is involved in the hydroperoxidase activity. Two conserved
charged residues, Arg120 and Glu524, are also located at the
entrance of the COX active site. Many NSAIDs bearing a
carboxylate function are known to form a salt bridge with Arg120
and to engage into hydrogen bonding with the phenolic hydroxyl of
Tyr355. Crystal structures of the COX enzymes with several
carboxylic acid-containing NSAIDs show that the inhibitors have
their carboxylate coordinated to Arg120 and their aromatic
functionality projecting into the cyclooxygenase active site toward
Tyr385 [27,28]. For example, recent molecular docking studies
indicate that the carboxylates of flurbiprofen, ketoprofen and
naproxen form a salt bridge with Arg120 and a hydrogen bond
with the phenolichydroxyl ofTyr355[29]. The three inhibitorsbind
to the same site and adopt similar conformations to those found in
the crystalstructuresofovine COX-1complexed withibuprofenand
flurbiprofen [30]. In fact, the carboxylate moiety can be in ortho,
meta or para positions with respect to the aromatic moiety of the
molecule. Notably, this seems to make a difference in the binding
modeoftheligands.Whenthecarboxylatemoietyisinmetaorpara,
the inhibitor binds in such a way that the carboxylate forms a salt
bridge with Arg120. In contrast, when the carboxylate moiety is in
ortho, ligands like diclofenac or meclofenamic acid bind in a
different orientation. The recent determination of the crystal
structure of diclofenac complexed with COX-2 demonstrates that
Figure 6. Effect of compound 15 on activation and deactivation kinetics of Kv7.2/3 channels. (A) Activation kinetics were evaluated at 220 mV by
determining t1/2 , the time value at which half of the current amplitude developed, in the absence or presence of 25 mM compound 15 (n=4; *
p,0.02). (B) Representative normalized trace of current activation in the absence and presence of 25 mM compound 15. (C) Representative
normalized trace of current deactivation at 260 mV in the absence and presence of 25 mM compound 15. (D) At 260 mV, deactivation kinetics were
fitted by one exponential function and the time constant was measured in the absence and presence of 25 mM compound 15 (n=4; * p,0.02).
doi:10.1371/journal.pone.0001332.g006
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carboxylate group being hydrogen-bonded to Tyr-385 and Ser-530,
a feature consistent with the structure of the complex arachidonic
acid-apoCOX-2 [31]. In addition, the phenyl group linked to the
acetic acid moiety of diclofenac was shown to formextensive van der
Waals interactions with several hydrophobic residues within the
active site [31].
How might carboxylate conversion into amide affect the COX
inhibition? The absence of a carboxylate group in compounds of
this study suggests that they probably interact differently from
diclofenac. It is likely that the amide bond is stiffer than the ester
bond, thus leading to a reduced flexibility of the CO-NH-C-C
bond, compared to the CO-O-C-C bond. If so, the flexibility of
the entire alkyl/ether chain would be altered, thus restricting the
number of chain conformations that could accommodate into the
active site pocket of the COX enzyme, mainly because of the
rigidity of this moiety. Interestingly, recent molecular dynamics
studies indicate that diclofenac and meclofenamic acid binding
modes need to occupy a larger region in the neighborhood of
Ser530 that is not required by other NSAIDs [32]. Similar features
have been previously observed for diphenylacetyl derivatives of
acetylcholine where replacement of ester by amide increases the
stiffness of the C-C bond, reduces the proportion of ‘gauche’
conformer and decreases the affinity for muscarinic acetylcholine
receptors [33]. In addition, esters are hydrogen-bond acceptors,
but cannot act as hydrogen-bond donors. Hence, Tyr-385 and
Ser-530 may form hydrogen bonds with the ester function instead
of the carboxylate of diclofenac, making the ester derivatives
potent COX inhibitors. In contrast, secondary amides can act as
hydrogen-bond donors and acceptors and may thus interact via a
very different hydrogen bonding network.
Considering theproperties of thecompoundspertaining to theM-
channelactivity,several contrasting features couldbe observed when
one compares them with those required for the COX inhibition.
First, the derivatization of the carboxylate into amide or ester is not
important fordisplayingM-channelproperties,instrikingcontrastto
its impact on COX enzyme inhibition. This is clearly exemplified by
compounds 8 and 2, which vis-a `-vis the M-channel target, can
accommodate with ester and amide functions, respectively, since
both are openers, while only ester compound 8 inhibits COX
activity. Second, thebridging secondaryamine of thediphenylamine
moiety of diclofenac and meclofenamate is not important for COX
inhibition and is not engaged in any close interactions with residues
of the COX active site, as previously shown in crystallographic data
[31]. In contrast, we found that compounds lacking this secondary
amine and still bearing a carboxylate (e.g., flurbiprofen, ketoprofen
or fenoprofen) do not activate Kv7.2/3 channels. This implies that
the bridging secondary amine function crucially interacts with an
electrophile or is engaged into hydrogen bonding within a hydro-
phobic pocket site of the M-channel. Along this line, we found that
aromatic ring deactivators (electron-withdrawing groups) like NO2
may increase the opener potency as shown by comparing
Figure 7. Compound 15 inhibits firing of hippocampal and peripheral DRG neurons. (A) Representative rat hippocampal spiking discharge, evoked
by a squared depolarizing current pulse (100 pA for 400 msec) before (control), during exposure to 25 mM compound 15 and after washout (wash).
(B) Resting membrane potential of DRG neurons before (control) and following exposure to 25 mM compound 15 (n=13; * p,0.01). (C)
Representative solitary spike evoked in DRG neurons by 2 ms squared depolarizing current pulses (100–1100 pA in 100 pA increments) in the
absence (control) or presence of 25 mM compound 15. (D) Number of spikes evoked by injecting squared depolarizing current pulses (75–200 pA for
400 ms) in hippocampal and DRG neurons in the absence and presence of 25 mM compound 15 (n=8; * p,0.01). (E) Rheobase current necessary to
inject (2 ms) into DRG neurons to evoke a solitary spike in the absence and presence of 25 mM compound 15 (n=12; * p,0.01).
doi:10.1371/journal.pone.0001332.g007
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our data indicate that a terminal hydroxyl group in the ether and
alkyl chain is absolutely required to generate an M-channel opener
(Figure 2). This functionality has two reactive covalent bonds,the C–
O and the O–H bonds, which are polarized so that oxygen is
electron rich and may potentially react with an electrophile while
hydrogen may be involved in hydrogen bonding. When the terminal
hydroxyl function has been removed, none of the derivatives
obtained are M-channel openers as exemplified by compounds 10,
12, 19 and 20.Remarkably, the crucial role of this terminal hydroxyl
function is further underscored when it is replaced by isobutyl,
ethylamine or 2,3-epoxypropyl groups in derivatives of the
diclofenac series, which generate M-channel blockers. This unique
feature is best illustrated by compound 13 which is a potent M-
channel blocker, yet based on the very same template, thus
suggesting that the opener and blocker molecules probably bind to
the samechannelsite. Indeed, thetinychangeof a hydroxylgroupto
amine functionality generates a compound that potently inhibits
recombinant Kv7.2/3 channels and induces a hyperexcitability state
in DRG neurons, which fire spontaneously upon compound 13
exposure. The dual function of M-channel blocker and COX
inhibitor exemplified by compound 13 may be of great therapeutic
advantage for treating memory deficits and Alzheimer’s disease.
Indeed, administration of NSAID agents is known to reduce the risk
of developing Alzheimer’s disease in normal aging populations [34],
an effect that may be reinforced by the cognitive enhancer action
obtained upon blockade of M-channels [14]. Similarly, the dual
function of compounds 8 or 15, as COX inhibitors and M-channel
openers, may produce synergistic effects in terms of pain
management. Thus, it may be potentially useful in some cases to
exploit the dual function of some derivatives to reinforce their
therapeutic value.
The good selectivity of the opener compound 6 for M-channels
versus other Kv channels, including the cardiac Kv11.1 (hERG or
IKR)a n dK v 7 . 1 / K C N E 1( IKS) and other neuronal K
+ currents, is
promising. IKR and IKS currents are essential for the normal
Figure 8. Effects of compound 15 on spontaneous glutamate and GABA release and on maximal electroshock seizure model in mice. (A)
Representative traces of spontaneous IPSCs recorded at a holding potential of 270 mV, before (control), during exposure to 25 mM compound 15
and after washout (wash). (B) Representative experiment showing sIPSCs frequency as a function of time, before, during exposure to 25 mM
compound 15 and after washout. (C) Effect of 25 mM compound 15 on normalized charge transfer, amplitude and frequency of sIPSCs (n=7; *
p,0.01). (D) Representative traces of spontaneous EPSCs recorded at a holding potential of 270 mV, before (control), during exposure to 25 mM
compound 15 and after washout (wash). (E) effect of 25 mM compound 15 on normalized burst duration, on frequency and charge transfer within
bursts and on total (F) charge transfer of sEPSCs (n=6; * p,0.01). (G) Compound 15 protects from epileptic seizures induced by the MES generalized
epilepsy model in mice (0.2 sec, 50 mA) with ED50 of 12 mg/kg.
doi:10.1371/journal.pone.0001332.g008
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encoding genes produce the long QT syndrome (LQT), a human
ventricular arrhythmia [35]. Common medications (antihistamines,
antiarrhythmics, antibiotics) can block the Kv11.1 (hERG) channel
and thereby depress the cardiac IKR current [36]. This side effect
leads to similar risks of lethal arrhythmia as those produced by the
inherited LQT syndrome. The lack of blocking effects of compound
6o nIKR and IKS currents opens interesting therapeutic perspectives
for these new derivatives. Noteworthy, compound 6 is selective for
Kv7.2/3 channels and does not activate Kv7.4, which is a distinctive
feature compared to that of the well known opener retigabine [37].
In all, this study reveals important determinants of COX
inhibition by the NSAID subfamilies of diclofenac and meclofe-
namic acid. The data also provide a structural framework for
tailoring powerful and selective M-channel modulators, including
openers and blockers. In addition, this study offers premises for
designing new NSAIDs.
METHODS
Synthesis of compounds
All details concerning the synthesis of compounds can be found in
the Supporting Text S1.
Recombinant expression of Kv7.2/3 channels in CHO
cells
Chinese hamster ovary (CHO) cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 2 mM
glutamine, 10% fetal calf serum and antibiotics. Briefly, 40,000
cells seeded on poly-D-lysine-coated glass coverslips (13 mm
diameter) in a 24-multiwell plate were transfected with pIRES-
CD8 (0.5 mg) as a marker for transfection, and with Kv7.2 (0.5 mg)
and Kv7.3 (0.5 mg). For electrophysiology, transfected cells were
visualized approximately 40 hours following transfection, using
anti-CD8 antibody-coated beads. Transfection was performed
Figure 9. Compound 6 enhances Kv7.2/3 currents and inhibits firing of peripheral DRG neurons. (A) Representative traces recorded from the same
CHO cell before (left panel) and after (right panel) external application 100 mM compound 6. The membrane potential was stepped from 290 mV
(holding potential) to +40 mV for 1.5 s pulse duration in 10mV increments, followed by a repolarizing step to 260 mV. (B) The normalized
conductance (G/Gmax) was plotted as a function of the test voltages, for control (open squares), 25 mM (solid squares) and 100 mM (empty circles)
compound 6-treated cells. The activation curves were fitted using one Boltzmann function (n=5). (C) The potency of compound 6 was determined by
the extent of left-shift (DV50), plotted as a function of compound 6 concentration and fitted by a sigmoidal function yielding an EC50 value of
1462 mM (n=5). (D) Representative rat DRG spiking discharge, evoked by a squared depolarizing current pulse (100 pA for 400 msec) before
(control), during exposure to 25 mM compound 6 and after washout (wash). (E) Rheobase current necessary to inject (2 ms) into DRG neurons to
evoke a solitary spike in the absence and presence of 25 mM compound 6 (n=8; * p,0.01). (F) Number of spikes evoked by injecting squared
depolarizing current pulses (75–200 pA for 400 ms) in DRG neurons in the absence and presence of 25 mM compound 6 (n=12; * p,0.01). (G)
Resting membrane potential of DRG neurons before (control) and following exposure to 25 mM compound 6 (n=7; * p,0.01).
doi:10.1371/journal.pone.0001332.g009
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manufacturer’s protocol.
Neuronal hippocampal and DRG primary cultures
For dorsal root ganglion (DRG) neuronal cultures, ganglia were
dissected from 2–5 day-old Sprague-Dawley rats killed by
decapitation. DRGs were placed in Hank’s balanced saline solution
(HBSS) and prepared by enzymatic dissociation. Briefly, after
30 min incubation in 5 mg/ml dispase, 2 mg/ml collagenase type
1A and 0.1 mg/ml DNase (Invitrogen/Gibco, Carlsbad, CA) in
Ca
2+ and Mg
2+-free HBSS, the ganglia were mechanically triturated
with a fire-polished glass Pasteur pipette. The ganglia were then
centrifuged for 5 min at 80xg and resuspended in DMEM
supplemented with 2 mM L-glutamine, 16.5 mM NaHCO3,6g / l
glucose, 5 ml penicillin/streptomycin and 10% fetal calf serum. For
electrophysiological recording, dissociated neurons were plated on
13 mm glass coverslips, previously coated with poly-D-lysine (1 mg/
ml) and laminin (10 mg/ml) and used at 1–2 days in culture.
For hippocampal neuronal cultures, Sprague-Dawley rat
embryos (E18) were removed by caesarian section and their
hippocampi were dissected out. The tissue was digested with
papain for 20 min, triturated to a single-cell suspension, and
plated at a density of 40,000 cells per ml on a substrate of bovine
collagen type IV and 100 mg/ml poly-L-lysine in 13 mm diameter
glass coverslips of a 24-multiwell plate. The culture medium
consisted of Modified Eagle’s Medium containing 5% horse serum
(Biological Industries, Beit HaEmek, Israel), B-27 neuronal
supplement (Invitrogen, Carlsbad, CA), 100 U/ml penicillin,
100 mg/ml streptomycin, and 2 mM glutamine. D-glucose was
supplemented to a final concentration of 6 g/l. Cytosine-1-D-
arabinofuranoside (5 mM) was added after 5 days to arrest glial
cell proliferation. For electrophysiological recordings hippocampal
neurons were used at 10–14 days in culture. All cultures were
maintained at 37uC in humidified air containing 5% CO2.
Maximal Electroshock seizure test
The anti-convulsant effect was measured by the maximal
electroshock seizure model (MES) in ICR mice as previously
described [7]. The procedures followed for experimentation and
maintenance of the animals were approved by the animal research
ethics committee of Tel Aviv University and in accordance with the
Guide for the Care and Use of Laboratory Animals (1996, National
Academy of Sciences, Washington DC). Briefly, maximal electro-
shock was induced in adult mice by means of two transcorneal
electrodes delivering an alternative current of 50 mA at 60 Hz for
0.2 sec using rodent shocker (Hugo Sachs Electronik, type 221).
This was shown to cause tonic convulsions in 100% of the animals
tested. The drugs dissolved in 0.9% saline were administered
intraperitoneally 30 min before the electroshock was performed.
Animals failing to show tonic hind limb extension were scored as
protected and were expressed in percentage.
Electrophysiology
Voltage-clamp recordings in CHO cells were performed, using the
whole-cell configuration of the patch-clamp technique. Signals
were amplified using an Axopatch 200B patch-clamp amplifier
(Molecular Devices, Sunnyvale, CA), sampled at 2 kHz and
filtered at 800 Hz via a 4-pole Bessel low pass filter. Data were
acquired using pClamp 9.2 software (Molecular Devices) and an
IBM compatible Pentium IV computer in conjunction with a
DigiData 1322A interface (Molecular Devices). The patch pipettes
were pulled from borosilicate glass (Warner Instrument Corp,
USA) with a resistance of 2–5 MV. For K
+ current recordings in
CHO cells, the intracellular pipette solution contained (in mM):
130 KCl, 1 MgCl2,5K 2ATP, 5 EGTA, 10 HEPES, adjusted with
KOH to pH 7.4 (290 mOsm). The extracellular solution
contained (in mM): 140 NaCl, 4 KCl, 1.8 CaCl2, 1.2 MgCl2,1 1
glucose, 5.5 HEPES, adjusted with NaOH to pH 7.4 (310 mOsm).
Series resistances (3–13 MV) were compensated (75–90%) and
periodically monitored.
For current-clamp recordings in primary cultured neurons, the
patch pipettes were filled with (in mM): 135 KCl, 1 K2ATP, 1
MgATP, 2 EGTA, 1.1 CaCl2, 5 glucose, 10 HEPES, adjusted with
KOH at pH 7.4 (315 mOsm). The external solution contained (in
mM): 150 NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2, 15 glucose, 10
HEPES, adjusted with NaOH at pH 7.4 (325 mOsm). Recordings
were sampled at 5 kHz and filtered at 2 KHz via a 4-pole Bessel
low pass filter. A liquid junction potential of about 215.6 mV was
measured between the intracellular and saline solutions and
corrected on-line. For evoking spike discharges, 75–200 pA square
depolarizing current pulses were injected into neurons for 400 ms.
For rheobase current measurements, 100–1100 pA square
depolarizing current pulses were injected into neurons for 2 ms.
Spontaneous excitatory postsynaptic currents (EPSCs) were
recorded in the voltage-clamp configuration of the whole-cell
patch-clamp technique at a holding potential of 270 mV as
previously described [38]; the extracellular solution contained (in
mM) 160 NaCl, 2.5 KCl, 10 HEPES, 10 glucose, 2 CaCl2; pH 7.3
(325 mOsm), to which 30 mM picrotoxin and 10 mM bicuculline
methyl iodide were added. The intracellular solution consisted (in
mM) of 130 K-gluconate, 10 KCl, 1.1 EGTA, 10 HEPES, 1
MgCl2,2N a 2ATP, 0.1 CaCl2 and 5 QX314Br to block Na
+
currents; pH 7.2 (315 mOsm). Spontaneous inhibitory postsynap-
tic currents (IPSCs) were recorded at a holding potential of
270 mV; the extracellular solution contained (in mM) 160 NaCl,
2.5 KCl, 10 HEPES, 10 glucose, 2 CaCl2; pH 7.3 (325 mOsm), to
which 10 mM NBQX and 10 mM AP-5 were added. The
intracellular solution consisted (in mM) of 144 CsCl, 10 HEPES,
1.1 EGTA, 0.1 CaCl2, 5 MgCl2,2N a 2ATP, 5 QX314 Br; pH 7.3
(315 mOsm).
Voltage-clamp measurements in Xenopus oocytes were per-
formed as previously described [7].
Table 2. Specificity of compound 6 on different K
+ channel
subtypes.
......................................................................
K
+ channel subtype Fold current amplitude
25 mM compound 6 50 mM compound 6
Kv11.1 or hERG (210 mV) 1.160.02 0.960.08
Kv1.2 (0 mV) 0.960.01 0.6660.03 *
Kv 2.1 (+30 mV) 1.260.09 1.260.11
Kv 4.3 (+30 mV) 1.160.04 1.060.07
Kv7.2 (240 mV) 3.560.4 * 6.860.7 *
Kv 7.4 (230 mV) 1.060.12 0.960.04
Kv 7.1 (+30 mV) 0.9360.02 0.7260.02 *
IKS (+30 mV) 1.0260.04 0.9760.04
The specificity of compound 6 at 25 mM and 50 mM towards various Kv
channels was tested in Xenopus oocytes, except for Kv1.2 which was checked in
transfected CHO cells. The current amplitude of the various Kv channels was
tested at the indicated voltages and the effect of the drugs was expressed as
fold of the control amplitude measured under the same conditions in the
absence of the drug. Data are expressed as mean6SEM of 5-7 separate
experiments. * significance p,0.01.
doi:10.1371/journal.pone.0001332.t002
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Data analysis was performed using the Clampfit program (pClamp
9.2, Molecular Devices), Microsoft Excel (Microsoft) and Prism 4.0
(GraphPad). Chord conductance (G) was calculated by using the
following equation:
G~I=(V{Vrev)
where I corresponds to the current amplitude measured at the end
of the pulse and Vrev, the calculated reversal potential. G was
estimated at various test voltages V and then, normalized to a
maximal conductance value, Gmax. Activation curves were fitted
by one Boltzmann distribution:
G=Gmax~1=f1zexp½(V50 V)=s g
where V50 is the voltage at which the current is half-activated and
s is the slope factor. All data were expressed as mean6SEM.
Statistically significant differences were assessed by Student’s t-test.
Analysis of sEPSCs and sIPSCs was done using the Clampfit
program (pClamp 9.2, Molecular Devices) and included evalua-
tion of the individual events as well as the average event amplitude
and the integral of the event (total charge transfer).
Cyclooxygenase inhibition assays
Mouse colon adenocarcinoma CT26 and mouse Lewis lung
carcinoma D122 cells were grown in DMEM (D122) or RPMI
(CT26) supplemented with 10% fetal calf serum, 4% glutamine,
1% penicillin-streptomycin-nystatin and 3% non essential amino
acids (D122) and maintained in a humidified 37uC incubator with
5% CO2. For the COX assays, cells were grown onto 24 multiwell
plates. Before the assay, cells were washed with serum-free
medium; then tested compounds were added to the medium and
incubated for 30 min at 37uC after which 30 mM arachidonic acid
was added and incubated for additional 20 min. At the end of the
incubations, 10 mM indomethacin was added to stop the reaction
and medium was transferred to another 24 multiwell plate for
measuring PGE2 production by radioimmunoassay (DuPont-
NEN; Boston, MA) according to manufacturer protocol. Protein
determination was assayed on scraped cells and was used to
normalize the amount of PGE2 production. Assays with purified
ovine COX-1 and human recombinant COX-2 were performed
using the COX inhibitor screening assay (Cayman chemical
company, Ann Arbor, MI), according to manufacturer protocol.
SUPPORTING INFORMATION
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DOC)
ACKNOWLEDGMENTS
Author Contributions
Conceived and designed the experiments: BA AP AR DS. Performed the
experiments: EM AP ND MT ED AG RN. Analyzed the data: BA EM AP
ND MT RN. Contributed reagents/materials/analysis tools: ED AG AR
DS. Wrote the paper: BA.
REFERENCES
1. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural,
cellular, and molecular biology. Annu Rev Biochem 69: 145–182.
2. Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA (1998) Differential
regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis
factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts.
Exp Cell Res 241: 222–229.
3. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev
Pharmacol Toxicol 38: 97–120.
4. Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:
1709–1711.
5. Solomon DH (2005) Selective cyclooxygenase 2 inhibitors and cardiovascular
events. Arthritis Rheum 52: 1968–1978.
6. Solomon DH, Glynn RJ, Levin R, Avorn J (2002) Nonsteroidal anti-
inflammatory drug use and acute myocardial infarction. Arch Intern Med
162: 1099–1104.
7. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, et al. (2005) Meclofenamic
acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel
openers, depress cortical neuron activity and exhibit anticonvulsant properties.
Molecular Pharmacology 67: 1053–1066.
8. Brown DA (1988) M-currents. In Ion channels. New York: Plenum. pp 55–99.
9. Gu N, Vervaeke K, Hu H, Storm JF (2005) Kv7/KCNQ/M and HCN/h, but
not KCa2/SK channels, contribute to the somatic medium after-hyperpolar-
ization and excitability control in CA1 hippocampal pyramidal cells. J Physiol
566: 689–715.
10. Jentsch TJ (2000) Neuronal KCNQ potassium channels:physiology and role in
diseases. Nature Neurosci 1: 21–30.
11. Marrion NV (1997) Control of M-current. Annu Rev Physiol 59: 483–504.
12. Yue C, Yaari Y (2004) KCNQ/M channels control spike afterdepolarization
and burst generation in hippocampal neurons. J Neurosci 24: 4614–4624.
13. Conte Camerino D, Tricarico D, Desaphy JF (2007) Ion channel pharmacology.
Neurotherapeutics 4: 184–198.
14. Robbins J (2001) KCNQ potassium channels: physiology, pathophysiology, and
pharmacology. Pharmacol Ther 90: 1–19.
15. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, et al. (1999)
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-
2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc
Natl Acad Sci U S A 96: 7563–7568.
16. Levin G, Duffin KL, Obukowicz MG, Hummert SL, Fujiwara H, et al. (2002)
Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid
by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis
of prostaglandin E1 and prostaglandin E2. Biochem J 365: 489–496.
17. Takahashi T, Baba M, Nishino H, Okuyama T (2006) Cyclooxygenase-2 plays a
suppressive role for induction of apoptosis in isoliquiritigenin-treated mouse
colon cancer cells. Cancer Lett 231: 319–325.
18. Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, et al. (2003)
KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci
23: 7227–7236.
19. Macdonald RL, Kelly KM (1995) Antiepileptic drug mechanisms of action.
epilepsia 36 (suppl 2): S2–S12.
20. Etxeberria A, Santana-Castro I, Regalado MP, Aivar P, Villarroel A (2004)
Three mechanisms underlie KCNQ2/3 heteromeric potassium M-channel
potentiation. J Neurosci 24: 9146–9152.
21. Galanakis D, Kourounakis AP, Tsiakitzis KC, Doulgkeris C, Rekka EA, et al.
(2004) Synthesis and pharmacological evaluation of amide conjugates of
NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and
antioxidant properties with significantly reduced gastrointestinal toxicity. Bioorg
Med Chem Lett 14: 3639–3643.
22. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, et al. (2000)
Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile
conversion of nonsteroidal antiinflammatory drugs to potent and highly selective
COX-2 inhibitors. Proc Natl Acad Sci U S A 97: 925–930.
23. Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ (2000)
Ester and amide derivatives of the nonsteroidal antiinflammatory drug,
indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 43:
2860–2870.
24. Kalgutkar AS, Rowlinson SW, Crews BC, Marnett LJ (2002) Amide derivatives
of meclofenamic acid as selective cyclooxygenase-2 inhibitors. Bioorg Med
Chem Lett 12: 521–524.
25. Sriram D, Yogeeswari P, Devakaram RV (2006) Synthesis, in vitro and in vivo
antimycobacterial activities of diclofenac acid hydrazones and amides. Bioorg
Med Chem 14: 3113–3118.
26. Luong C, Miller A, Barnett J, Chow J, Ramesha C, et al. (1996) Flexibility of the
NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol
3: 927–933.
A Tale of Switched Functions
PLoS ONE | www.plosone.org 12 December 2007 | Issue 12 | e133227. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, et al.
(1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-
inflammatory agents. Nature 384: 644–648.
28. Picot D, Loll PJ, Garavito RM (1994) The X-ray crystal structure of the
membrane protein prostaglandin H2 synthase-1. Nature 367: 243–249.
29. Pouplana R, Lozano JJ, Ruiz J (2002) Molecular modelling of the differential
interaction between several non-steroidal anti-inflammatory drugs and human
prostaglandin endoperoxide H synthase-2 (h-PGHS-2). J Mol Graph Model 20:
329–343.
30. Selinsky BS, Gupta K, Sharkey CT, Loll PJ (2001) Structural analysis of NSAID
binding by prostaglandin H2 synthase: time-dependent and time-independent
inhibitors elicit identical enzyme conformations. Biochemistry 40: 5172–5180.
31. Rowlinson SW, Kiefer JR, Prusakiewicz JJ, Pawlitz JL, Kozak KR, et al. (2003)
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with
Ser-530 and Tyr-385. J Biol Chem 278: 45763–45769.
32. Llorens O, Perez JJ, Palomer A, Mauleon D (2002) Differential binding mode of
diverse cyclooxygenase inhibitors. J Mol Graph Model 20: 359–371.
33. Barlow RB, Bremner JB, Soh KS (1978) The effects of replacing ester by amide
on the biological properties of compounds related to acetylcholine.
Br J Pharmacol 62: 39–50.
34. Hoozemans JJ, O’Banion MK (2005) The role of COX-1 and COX-2 in
Alzheimer’s disease pathology and the therapeutic potentials of non-steroidal
anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 4: 307–315.
35. Nerbonne JM, Kass RS (2005) Molecular physiology of cardiac repolarization.
Physiological Reviews 85: 1205–1253.
36. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and
cardiac arrhythmia. Nature 440: 463–469.
37. Tatulian L, Delmas P, Abogadie FC, Brown DA (2001) Activation of expressed
KCNQ potassium currents and native neuronal M-type potassium currents by
the anti-convulsant drug retigabine. J Neurosci 21: 5535–5545.
38. Peretz A, Sheinin A, Yue C, Degani-Katzav N, Gibor G, et al. (2007) Pre- and
postsynaptic activation of M-channels by a novel opener dampens neuronal
firing and transmitter release. J Neurophysiol 97: 283–295.
A Tale of Switched Functions
PLoS ONE | www.plosone.org 13 December 2007 | Issue 12 | e1332